News Home

Should You Buy Meridian Bioscience, Inc. (VIVO) Stock After it Has Fallen 0.25% in a Week?

Wednesday, September 28, 2022 03:43 PM | InvestorsObserver Analysts
Should You Buy Meridian Bioscience, Inc. (VIVO) Stock After it Has Fallen 0.25% in a Week?

The market has been down on Meridian Bioscience, Inc. (VIVO) stock recently. VIVO gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bearish
Meridian Bioscience, Inc. has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on VIVO!

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With VIVO Stock Today?

Meridian Bioscience, Inc. (VIVO) stock is trading at $31.94 as of 3:42 PM on Wednesday, Sep 28, a rise of $0.31, or 0.98% from the previous closing price of $31.63. The stock has traded between $31.17 and $32.02 so far today. Volume today is light. So far 173,100 shares have traded compared to average volume of 350,111 shares. To screen for more stocks like Meridian Bioscience, Inc. click here.

More About Meridian Bioscience, Inc.

Meridian Bioscience Inc is an integrated life science company. It develops and distributes diagnostic tests and reagents, as well as biologic substances used by pharmaceutical and biotechnology companies. Its Diagnostics segment manufactures tests primarily for gastrointestinal, viral, respiratory, & parasitic infectious diseases. Its testing platforms include isothermal DNA amplification, rapid immunoassays, and enzyme-linked immunoassays. The Life sciences segment sells b-antigens, antibodies, and reagents in bulk to other diagnostic manufacturers, the agriculture industry, and researchers. It also manufactures proteins that biopharmaceutical companies use in new drugs and vaccines. The entity has a business presence in the US and other countries. Click Here to get the full Stock Report for Meridian Bioscience, Inc. stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App